IGGA
CLRB icon

Iron Gate Global Advisors’s Cellectar Biosciences CLRB Stock Holding History

Iron Gate Global Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3
Closed -$2K – 101
2018
Q3 		$2K Sell
3
-7
-70% -$8.24K ﹤0.01% 216
2018
Q2 		$19K Buy
10
+5
+100% +$15.4K 0.01% 124
2018
Q1 		$15K Hold
5
– – 0.01% 56
2017
Q4 		$22K Buy
+5
New +$22.3K 0.02% 51

Other funds holding CLRB

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Iron Gate Global Advisors's CLRB Position: Q4 2018 in Review

Iron Gate Global Advisors sold out of Cellectar Biosciences (CLRB) in Q4 2018, closing a stake of 3 shares — an estimated $2K sold.

Iron Gate Global Advisors first reported a position in CLRB in Q4 2017 and held it in 4 quarters. The position peaked at $22K in Q4 2017. 11 funds tracked by Wall St. Rank hold CLRB as of Q4 2018.

  • Iron Gate Global Advisors reported no remaining Cellectar Biosciences position as of Q4 2018 after selling out during the quarter.
  • Iron Gate Global Advisors sold 3 Cellectar Biosciences shares in Q4 2018, an estimated $2K.
  • Iron Gate Global Advisors first reported a position in Cellectar Biosciences in Q4 2017 and held it in 4 quarters.
  • Iron Gate Global Advisors's Cellectar Biosciences position peaked at $22K in Q4 2017.
  • 11 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2018.

Based on Iron Gate Global Advisors's 13F filing for Q4 2018, filed 19 Feb 2019.